Modeling the Relationships Among Late-Life Body Mass Index, Cerebrovascular Disease, and Alzheimer's Disease Neuropathology in an Autopsy Sample of 1,421 Subjects from the National Alzheimer's Coordinating Center Data Set
- PMID: 28304301
- PMCID: PMC5526463
- DOI: 10.3233/JAD-161205
Modeling the Relationships Among Late-Life Body Mass Index, Cerebrovascular Disease, and Alzheimer's Disease Neuropathology in an Autopsy Sample of 1,421 Subjects from the National Alzheimer's Coordinating Center Data Set
Abstract
The relationship between late-life body mass index (BMI) and Alzheimer's disease (AD) is poorly understood due to the lack of research in samples with autopsy-confirmed AD neuropathology (ADNP). The role of cerebrovascular disease (CVD) in the interplay between late-life BMI and ADNP is unclear. We conducted a retrospective longitudinal investigation and used joint modeling of linear mixed effects to investigate causal relationships among repeated antemortem BMI measurements, CVD (quantified neuropathologically), and ADNP in an autopsy sample of subjects across the AD clinical continuum. The sample included 1,421 subjects from the National Alzheimer's Coordinating Center's Uniform Data Set and Neuropathology Data Set with diagnoses of normal cognition (NC; n = 234), mild cognitive impairment (MCI; n = 201), or AD dementia (n = 986). ADNP was defined as moderate to frequent neuritic plaques and Braak stageIII-VI. Ischemic Injury Scale (IIS) operationalized CVD. Joint modeling examined relationships among BMI, IIS, and ADNP in the overall sample and stratified by initial visit Clinical Dementia Rating score. Subject-specific random intercept for BMI was the predictor for ADNP due to minimal BMI change (p = 0.3028). Analyses controlling for demographic variables and APOE ɛ4 showed lower late-life BMI predicted increased odds of ADNP in the overall sample (p < 0.001), and in subjects with CDR of 0 (p = 0.0021) and 0.5 (p = 0.0012), but not ≥1.0 (p = 0.2012). Although higher IIS predicted greater odds of ADNP (p < 0.0001), BMI did not predict IIS (p = 0.2814). The current findings confirm lower late-life BMI confers increased odds for ADNP. Lower late-life BMI may be a preclinical indicator of underlying ADNP.
Keywords: Alzheimer’s disease; body mass index; cerebrovascular disease; neuropathology; obesity.
Conflict of interest statement
For the remaining authors, there are no conflicts of interest to declare.
Figures


Similar articles
-
A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology.J Alzheimers Dis. 2018;63(4):1347-1360. doi: 10.3233/JAD-180017. J Alzheimers Dis. 2018. PMID: 29843242 Free PMC article.
-
The Contribution of Cerebral Vascular Neuropathology to Mild Stage of Alzheimer's Dementia Using the NACC Database.Curr Alzheimer Res. 2020;17(13):1167-1176. doi: 10.2174/1567205018666210212160902. Curr Alzheimer Res. 2020. PMID: 33583381 Free PMC article.
-
Late-Life Vascular Risk Factors and Alzheimer Disease Neuropathology in Individuals with Normal Cognition.J Neuropathol Exp Neurol. 2016 Oct;75(10):955-962. doi: 10.1093/jnen/nlw072. Epub 2016 Aug 11. J Neuropathol Exp Neurol. 2016. PMID: 27516116 Free PMC article.
-
Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy.J Neuropathol Exp Neurol. 2020 May 1;79(5):465-473. doi: 10.1093/jnen/nlaa014. J Neuropathol Exp Neurol. 2020. PMID: 32186726 Free PMC article. Review.
-
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. Alzheimers Dement. 2018. PMID: 29653606 Free PMC article. Review.
Cited by
-
A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology.J Alzheimers Dis. 2018;63(4):1347-1360. doi: 10.3233/JAD-180017. J Alzheimers Dis. 2018. PMID: 29843242 Free PMC article.
-
The Association Between Neuropathological Lesions and Body Mass Index Is Independent of Cognitive Abilities.J Alzheimers Dis. 2024;101(3):773-785. doi: 10.3233/JAD-231366. J Alzheimers Dis. 2024. PMID: 39213060 Free PMC article.
-
Patterns of Aging Changes in Bodyweight May Predict Alzheimer's Disease.J Alzheimers Dis. 2024;97(1):163-170. doi: 10.3233/JAD-220998. J Alzheimers Dis. 2024. PMID: 38108347 Free PMC article.
-
Hypertension and Alzheimer's disease: indirect effects through circle of Willis atherosclerosis.Brain Commun. 2020 Jul 21;2(2):fcaa114. doi: 10.1093/braincomms/fcaa114. eCollection 2020. Brain Commun. 2020. PMID: 33543127 Free PMC article.
-
Data-Driven Analyses of Longitudinal Hippocampal Imaging Trajectories: Discrimination and Biomarker Prediction of Change Classes.J Alzheimers Dis. 2022;88(1):97-115. doi: 10.3233/JAD-215289. J Alzheimers Dis. 2022. PMID: 35570482 Free PMC article.
References
-
- Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8:1–13. - PMC - PubMed
-
- Khan TK, Alkon DL. Alzheimer’s Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy. J Alzheimers Dis. 2015;46:817–36. - PubMed
-
- Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Palsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landen M, Minthon L, Blennow K, Zetterberg H, Hansson O Alzheimer’s Disease Neuroimaging I. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry. 2014;71:1183–91. - PubMed
Publication types
MeSH terms
Grants and funding
- P30 AG013854/AG/NIA NIH HHS/United States
- P50 AG005142/AG/NIA NIH HHS/United States
- U01 NS086659/NS/NINDS NIH HHS/United States
- P30 AG013846/AG/NIA NIH HHS/United States
- K23 NS102399/NS/NINDS NIH HHS/United States
- P50 AG016573/AG/NIA NIH HHS/United States
- P30 AG010161/AG/NIA NIH HHS/United States
- P50 AG025688/AG/NIA NIH HHS/United States
- P50 AG005133/AG/NIA NIH HHS/United States
- P50 AG005138/AG/NIA NIH HHS/United States
- R56 NS078337/NS/NINDS NIH HHS/United States
- P30 AG019610/AG/NIA NIH HHS/United States
- P50 AG033514/AG/NIA NIH HHS/United States
- UL1 TR001430/TR/NCATS NIH HHS/United States
- P30 AG010124/AG/NIA NIH HHS/United States
- P50 AG023501/AG/NIA NIH HHS/United States
- P50 AG005131/AG/NIA NIH HHS/United States
- P30 AG010133/AG/NIA NIH HHS/United States
- P50 AG016574/AG/NIA NIH HHS/United States
- P50 AG005146/AG/NIA NIH HHS/United States
- P30 AG035982/AG/NIA NIH HHS/United States
- P50 AG008702/AG/NIA NIH HHS/United States
- U01 AG016976/AG/NIA NIH HHS/United States
- U01 NS093334/NS/NINDS NIH HHS/United States
- P30 AG008051/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- P50 AG005136/AG/NIA NIH HHS/United States
- P30 AG012300/AG/NIA NIH HHS/United States
- P50 AG016570/AG/NIA NIH HHS/United States
- P50 AG005134/AG/NIA NIH HHS/United States
- P30 AG008017/AG/NIA NIH HHS/United States
- R01 NS078337/NS/NINDS NIH HHS/United States
- P30 AG010129/AG/NIA NIH HHS/United States
- P30 AG028383/AG/NIA NIH HHS/United States
- F32 NS096803/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous